India, July 8 -- The Indian pharmaceuticals sector seems to be at a new stage of evolution wherein mere scale will not work anymore. With increased pressure on prices in generic medicines in the international market, increased competition and the trend towards more sophisticated drugs, pharmaceutical firms have had to spend heavily on innovation, product differentiation and global production facilities.

In this scenario, the largest pharma firm of India in terms of volume sales is trying to exploit its dominant position by creating various sources of future growth. For FY26, this was yet another landmark year for the company. Revenue for the year stood at an all-time high level of Rs 28,163 crore, while the EBITDA and PAT margins stood ...